ResearcherTokyo Women's Medical UniversityNo recent work listed

Katsutoshi Tokushige

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1004-7369; OpenAlex author ID A5055210740. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 2

Risk factors for fatty pancreas and effects of fatty infiltration on pancreatic cancer. Last author DOI 10.3389/fphys.2023.1243983 ↗
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. Last author DOI 10.1007/s00280-018-3611-y ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Nao Otsuka · 2 shared papers, 2018–2023 · strength 0.36
- Paper Risk factors for fatty pancreas and effects of fatty infiltration on pancreatic cancer. DOI 10.3389/fphys.2023.1243983 ↗
- Paper Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. DOI 10.1007/s00280-018-3611-y ↗
Junko Tahara · 1 shared paper, 2018 · strength 0.10
- Paper Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. DOI 10.1007/s00280-018-3611-y ↗
Yukiko Takayama · 1 shared paper, 2018 · strength 0.10
- Paper Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. DOI 10.1007/s00280-018-3611-y ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.